REG - Roquefort Theraptcs. - Extension of Convertible Loan Notes

Roquefort TherapeuticsAnnouncement

23/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW8808Ja&default-theme=true

RNS Number : 8808J  Roquefort Therapeutics PLC  23 May 2025

23 May 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Extension of Convertible Loan Notes

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, announces that it has agreed with the
holders of its convertible loan notes ("CLNs") to extend the maturity date to
31 December 2025.

 

On 23 May 2024 the Board resolved to issue CLNs with a total face value of
£655,000. After taking into account previous conversions, there are currently
CLNs with a total face value of £307,894 outstanding ("Remaining CLNs"). The
Remaining CLNs were due to mature today ("Maturity Date"); however, the
Company has agreed with the holders of the Remaining CLNs to extend the
Maturity Date to 31 December 2025.  All other terms and conditions of the
CLNs remain unchanged.

 

Stephen West, Roquefort Therapeutics Chairman commented:

"We are pleased that the holders of the Remaining CLNs have agreed to extend
the maturity date to the end of the year. This allows us sufficient time to
focus on completing the previously announced Lyramid and Oncogeni
transactions, whilst assessing other clinical stage assets and/or revenue
generating life science businesses for possible M&A activity."

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker)                  +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                             +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the
immunology and oncology markets prior to securing a value accretive exit.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical anti-cancer and immunology assets.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLLLLEELBBBV